MedTrace Logo

68Ga-citrate PET/MR Imaging for Glioma

NCT03335280 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2020-05-01

No results posted yet for this study

Summary

This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.

Conditions

Interventions

DRUG

68Ga-citrate PET/MR

Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.

Sponsors & Collaborators

  • American Brain Tumor Association

    collaborator OTHER

  • Susan Chang

    lead OTHER

Principal Investigators

  • Susan Chang, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-26
Primary Completion
2020-04-24
Completion
2020-04-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03335280 on ClinicalTrials.gov